anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients with compensated disease. We aimed for the analysis of real-world data on the off-label use of bulevirtide in the setting of decompensated liver cirrhosis.
APPROACH AND RESULTS: We conducted a retrospective study in patients with HDV with decompensated liver disease at German, Austrian, and Italian centers. We included 19 patients (47% male, mean age: 51 years) with liver cirrhosis Child-Pugh B. The median MELD score was 12 (range 9-17) at treatment initiation. The median observation period was 41 weeks. Virologic response was achieved in 74% and normal alanine aminotransferase was observed in 74%. The combined response was achieved by 42%. The most relevant adverse events included self-limited alanine aminotransferase flares, an asymptomatic increase in bile acids, and the need for liver transplantation. Despite bile acid increases, adverse events were considered unrelated. Clinical and laboratory improvement from Child-Pugh B to A occurred in 47% (n = 9/19). Improvements in the amount of ascites were observed in 58% of the patients initially presenting with ascites (n = 7/12).
CONCLUSIONS: This report on off-label bulevirtide treatment in patients with decompensated HDV cirrhosis shows similar virologic and biochemical response rates as observed in compensated liver disease. Significant improvements were observed in surrogates of hepatic function and portal hypertension. However, this improvement was not seen in all patients. Controlled trials are needed to confirm the safety and efficacy of bulevirtide in decompensated HDV cirrhosis.
Extracorporeal centrifugal blood pumps are used to treat cardiogenic shock. Owing to the imbalanced excitation or initial assembly configurations, the variation in the impeller axial position has the potential to affect the blood pump performance. This study compared the hydrodynamics and hemolysis outcomes at different impeller axial positions via numerical simulations. The result shows that pressure difference of the blood pump decreased with increasing impeller axial position, with decreasing by 4.5% at a flow rate of 2 L/min. Under axial impeller motion close to the top pump casing, average wall shear stress and scalar shear stress reached their maximum values (64.2 and 29.1 Pa, respectively). The residence time in the impeller center hole and bottom clearance were extended to 0.5 s by increasing impeller axial position. Compared to the baseline blood pump, hemolysis index increased by 12.3% and 24.3% when impeller axial position is 2.5 and 4.0 mm, respectively. As a novelty, the findings reveal that the impeller axial position adversely affects hemolysis performance when the impeller is close to the pump casing. Therefore, in the development process of centrifugal blood pumps, the optimal axial position of the impeller must be defined to ensure hemodynamic performance.
<P>PROBLEM TO BE SOLVED: To provide a new nitrogen-containing fused-ring compound usable as an anti-HIV agent or a pharmaceutically acceptable salt.  <P>SOLUTION: The nitrogen-containing fused-ring compound represented by general formula [I], or the pharmaceutically acceptable salt thereof, and the anti-HIV agent containing such compound are provided. 2-(3,4-Dichlorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,8-dione hydrochloride is cited as a concrete example. The compound has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Drowsiness occurs in over 20% of patients treated with Zonalon® Cream, especially in patients receiving treatment to greater than 10% of their body surface area. Patients should be warned about the possibility of sedation and cautioned against driving a motor vehicle or operating hazardous machinery while being treated with Zonalon® Cream.

The sedating effects of alcoholic beverages, antihistamines, and other CNS depressants may be potentiated when Zonalon® Cream is used.

If excessive drowsiness occurs it may be necessary to reduce the frequency of applications, the amount of cream applied, and/or the percentage of body surface area treated, or discontinue the drug. However, the efficacy with reduced frequency of applications has not been established.

Keep this product away from the eyes.
A computer-implemented method of generating a set of goals is presented. The method entails receiving user input that includes items and an input value associated with each of the items. Individual values are assigned to the items based on the input value. The individual values are then summed to generate a total value, and the items are ranked according to the contributions of their respective individual values to the total value. A difference between the total value and a corresponding reference value is determined. The input value that is associated with the highest-ranking item is changed, and the total value and the difference are then recalculated using the changed input value. The process is repeated with the next highest-ranked item and the next until a condition is fulfilled. A goal is defined based on the changed input value of the items at the time the condition is fulfilled.
We reviewed the incidence and management of complications after total wrist arthroplasty, as reported in the literature, with so-called fourth-generation implants and other recent designs. While early intraoperative and postoperative complications, including fractures, tendon lacerations, infection, nerve compression, tendonitis, stiffness and chronic regional pain syndrome, had an acceptable incidence, late complications, such as periprosthetic osteolysis and implant loosening, occurred more frequently. Implant survival at 10 years was in the range of 70%-80% in most publications. Several of the implants have been modified or withdrawn. Instability and dislocation were frequent after a pyrocarbon spacer. Failed arthroplasties can be salvaged by revision arthroplasty or total wrist arthrodesis. Revision arthroplasty has a lower survival rate than primary arthroplasty and does not clearly offer important significant advantages over total wrist arthrodesis in terms of patient-reported outcome measures. Further development of prosthetic design, new materials and more knowledge on patient-related risk factors are needed.
Coronary artery disease (CAD) often leads to adverse events resulting in significant disease burdens. Underlying risk factors often remain inapparent prior to disease incidence and the cardiovascular (CV) risk is not exclusively explained by traditional risk factors. Platelets inherently promote atheroprogression and enhanced platelet functions and distinct platelet lipid species are associated with disease severity in patients with CAD. Lipidomics data were acquired using mass spectrometry and processed alongside clinical data applying machine learning to model estimates of an increased CV risk in a consecutive CAD cohort (n = 595). By training machine learning models on CV risk measurements, stratification of CAD patients resulted in a phenotyping of risk groups. We found that distinct platelet lipids are associated with an increased CV or bleeding risk and independently predict adverse events. Notably, the addition of platelet lipids to conventional risk factors resulted in an increased diagnostic accuracy of patients with adverse CV events. Thus, patients with aberrant platelet lipid signatures and platelet functions are at elevated risk to develop adverse CV events. Machine learning combining platelet lipidome data and common clinical parameters demonstrated an increased diagnostic value in patients with CAD and might improve early risk discrimination and classification for CV events.
PURPOSE: To obtain a basic pharmaceutical solution for softgel filling or two piece encapsulation or tablet production, containing a basic pharmaceutical agent and a mixed solvent and highly concentrated in order to enhance the solubility of medicines by partial ionization. CONSTITUTION: This pharmaceutical solution comprises a basic pharmaceutical agent (e.g. cimetidine or nifedipine) and a mixed solvent containing 10-80 wt.% polyethylene glycol having 200-800 average molecular weight, hydrogen ion in an amount necessary to increase solubility and 1-20 wt.% water. Since the hydrogen ion partially ionizes the basic pharameutial agent, the basic pharmaceutical agent is present in the state dissolved in both forms of free acid and its salt. The solvent system can be sealed into small-sized soft gel or two piece capsule capable of readily ingesting and the solid solution is suitable for producing tablets. The solution is useful for prescription for injection and application in animal pharmaceutical agents.
The aim of the present study was to investigate the effects of time, temperature, and burial in a natural environment on the viability of chondrocytes in porcine femoral condyles using confocal laser scanning microscopy. Hind trotters from 10 pigs were buried or left unburied. Samples were collected daily and stained with a combination of vital dyes (calcein-AM and ethidium homodimer-1). The chondrocytes showed an intense staining corresponding to their vitality. In the first 3 days, viability decreased slowly and showed no statistical difference between buried and unburied samples. After the first 3 days, it decreased rapidly, with the viability of the buried samples being 66% on day 4, decreasing to 25% on day 8 and to 16% on day 10, while in the unburied samples it decreased to 43% on day 4, 13% on day 8 and 5% on day 10. Our results indicate a time, temperature, and burial dependent decrease in chondrocyte viability and suggest the use of chondrocyte viability as a marker for estimating PMI in both the natural environment and in animals, as well as its potential use in humans.
Serotonergic antidepressants, including mirtazapine orally disintegrating tablets, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7)]. Serotonin syndrome can also occur when these drugs are used alone.

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of mirtazapine orally disintegrating tablets with MAOIs is contraindicated. In addition, do not initiate mirtazapine orally disintegrating tablets in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking mirtazapine orally disintegrating tablets, discontinue mirtazapine orally disintegrating tablets before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7)].

Monitor all patients taking mirtazapine orally disintegrating tablets for the emergence of serotonin syndrome. Discontinue treatment with mirtazapine orally disintegrating tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of mirtazapine orally disintegrating tablets with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
1. An experienced sonographer performed ultrasonographic examination with the subject in the supine position and heads rotated contralaterally to the examination side. A 5-12 MHz linear-array ultrasound transducer was used to observe both longitudinal and transverse views of bilateral SCM muscles for each subject. The ultrasound system settings, including gain (86%), monitor dynamic range (70 dB), and depth (2 cm), were kept constant throughout the study.
2. The echo intensity was determined by computer-assisted gray scale analysis and was calculated in MATLAB 2006b. The mean echo intensity of every pixel in the region of interest and the K value developed to compare sonograms between different individuals or between different times in the same subject were estimated as the previous study (PMID: 22215768)
COPD exacerbation is a common complication that significantly contributes to the high morbidity, mortality and costs associated with COPD. COPD exacerbations are associated with heightened lung inflammation that may have systemic implications (e.g., peripheral muscle weakness, cognitive impairment, depression, stroke, acute coronary syndrome, and atherosclerosis). Statins are potent agents that significantly reduce vascular events in patients with increased risks due to prior cardiac or cerebral vascular events and elevated lipid profiles. Statins have pleiotropic effects that extend well beyond their lipid lowering effects and may be potent anti-inflammatory agents. Retrospective data conducted in COPD patients indicate that statin use is associated with markedly decreased rates of COPD hospitalization and stabilization of lung function. Decreases in mortality in COPD due to complications of flu-like illnesses and deaths due to cardiovascular events have also been reported. Inflammatory biomarkers (C-reactive protein and interleukin- 6) are reported to be elevated in moderate to severe COPD patients who are prone to exacerbations. Inflammatory biomarkers (C-reactive protein and interleukin- 6) are reported to be reduced by statin therapy in patients with hyperlipidemia and cardiovascular diseases. Treatments that can effectively lessen the prevalence and severity of COPD exacerbations are desperately needed
Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
The ability to execute purposeful movements relies on sensory information coming from the body. This sensory information tells us where are limbs are in relation to the rest of our body (posture sense), how fast they are moving (kinesthetic sense), how forcefully we are making a contraction (muscular sense) and if we are being contacted by external objects, changes in temperature, pain, etc (somatic sense). Without these senses, the investigators could not make well-controlled movements or navigate in our environment safely. Because of the importance of these sensory inputs, the nervous system has designed a highly regulated system to control the amount and quality of sensory inflow entering into both the spinal cord and brain. The investigators wish to re-investigate how sensory pathways from our body controls the inflow of sensory inputs in adults with and without neurological injury. Specifically, the investigators want to test if the long-lasting suppression of sensory inflow by other sensory nerves is regulated by GABA-B receptors. The investigators will test this by giving participants the GABA-B receptor agonist baclofen. Nerve stimulation and muscle responses will be used to understand how sensory transmission is being controlled in the spinal cord and the GABA-B receptors involvement. Results from these studies will provide important fundamental information about how normal sensory inflow is controlled so that the investigators can better understand how it may be altered after injury to the brain and spinal cord. This information will open new avenues of study into the treatment of sensory-related dysfunction such as spasticity and motor incoordination that occurs after central nervous system injury or disease.
Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
A subclinical epizootic of chronic active gastritis, gastric erosions and presence of H. pylori-like bacteria was previously observed in a Cynomolgus monkey colony. The present study was to determine whether the bacteria were H. pylori, to characterize the strains, and to evaluate whether the presence of virulence genes was correlated with clinical pathology. Gastric specimens from a subgroup of 12 animals found positive by histology were cultured, and Random Amplification of Polymorphic DNA (RAPD) technique was used to fingerprint 19 strains isolated from five of these animals. Strains isolated from monkeys bred in Vietnam had an identical pattern, which was different from that of strains isolated from a monkey bred in the Philippines. All isolates were of the s1 a vacA subtype, but "Vietnamese" isolates were cagA+ and iceA1+, whereas "Philippino" isolates were cagA- and iceA2+. The 16S rRNA gene of one "Vietnamese" and one "Philippino" isolate was sequenced and compared with H. pylori sequences reported in GenBank. Sequences were 98.6 to 99.6 homologous with the 16S rRNA of ten H. pylori isolates, whereas the homology of H. acynonix was 94.7% and that of other Helicobacter species was <90%. In addition, strains isolated from these animals varied according to the country of origin, thus indicating probable infection prior to importation. These observations demonstrate that the epizootic of gastritis observed in Cynomolgus monkeys was caused by H. pylori, and that the Cynomolgus monkey may be a useful model to investigate the role of H. pylori in ulcerogenesis.
PURPOSE: A composition containing piperidine compounds which is an inhibitor of peroxiredoxin activity is provided to treat and prevent cancer. CONSTITUTION: A pharmaceutical composition for preventing and treating cancer suppresses Prx I activation. The composition contains piperidine compounds of chemical formula I, isomer, and pharmacologically acceptable salt as an active ingredient. In general formula I, P is phenyl group or pyrrol group; X is ketone group(C=O) or sulfonyl group(SO_2); and Q is hydrogen, halogen, methoxy group, ethoxy group, phenyl group, phenyl amine group, or styrene group. An inhibitor of Prx I activation contains the piperidine compounds of chemical formula I as an active ingredient. An anti-cancer drug contaisn the piperidine compounds, isomer, pharmaceutically acceptabke salt as an active ingredient.
A Mycobacterium bovis BCG polypeptide having a molecular mass of about 64 kD was found to be useful as an immunogen inducing resistance to autoimmune arthritis and similar autoimmune diseases. The invention relates to methods of treatment and diagnosis of autoimmune diseases especially arthritic conditions, in which said polypeptide is used. The invention also relates to a polypeptide comprising the epitope essential for this activity. The polypeptide has the formula  <IMAGE>  <IMAGE>  <IMAGE>  Further, the invention relates to polypeptides showing sequential homology with said polypeptide, and to derivatives and multimers thereof. Also, microorganisms expressing the polypeptides either as such or as part of a fusion protein or as a multimer, form part of the invention. Finally, the invention relates to pharmaceutical compositions, diagnostic compositions and test kits comprising a compound according to the invention.
PURPOSE: An antimicrobial composition including Anthriscus sylvestris extracts is provided to improve antibacterial activity against Helicobacter pylori, Escherichia coli, and staphylococcus aureus, thereby being used for prevention and treatment of diseases caused by pathogenic bacteria. CONSTITUTION: An antimicrobial composition including Anthriscus sylvestris extracts includes Anthriscus sylvestris extracts as active ingredients. The extract from Anthriscus sylvestris is extracted as alcohol having 1-4 carbons or a mixed solvent thereof. The extract from Anthriscus sylvestris has antibacterial activity against Helicobacter pylori, Escherichia coli, and staphylococcus aureus. A pharmaceutical composition for antibiotic includes falcarindiol or deoxypodophyllotoxin as an active ingredient. Falcarindiol or dioxy podophyllotoxin is obtained from the Anthriscus sylvestris. A pharmaceutical composition for duodenal disease prevention and treating includes extract from Anthriscus sylvestris as an active ingredient.